Affiliations: [a] Department of Gynecology, Huizhou No. 2 Women’s and Children’s Healthcare Hospital, Huizhou, Guangdong 516001, China | [b] Huizhou College of Life Sciences, Huizhou, Guangdong 516001, China | [c] Department of Gynecology, Shandong Provincial Tumor Hospital, Jinan, Shandong 250117, China | [d] Department of Gynecology, Shenyang Maternal and Child Hospital, Shenyang, Liaoning 110000, China
Correspondence:
[*]
Corresponding author: Li-Ya Zhang, Department of Gynecology, Huizhou No. 2 Women’s and Children’s Healthcare Hospital, No. 10, Daling Road, Huizhou, Guangdong 516001, China. Tel.: +86 13824208387; E-mail: zhangliya0110@163.com.
Abstract: BACKGROUND: Ovarian cancer (OC) is the fifth most common type of cancer in women worldwide. MiR-27a plays an important role in the development of ovarian cancer. However, the exact function and molecular mechanism of miR-27a in epithelial-mesenchymal transition (EMT) has not been thoroughly elucidated to date. METHODS: Quantitative real-time PCR (qRT-PCR) was used to determine the expression of miR-27a and FOXO1 mRNA in ovarian tissues and cells. The function of miR-27a in ovarian cancer was investigated through overexpression and knockdown of miR-27a in vitro. Wound healing and Transwell assays were performed to evaluate the migration and invasive capacity of the cells. A luciferase reporter assay was conducted to confirm the interaction between miR-27a and FOXO1. Western blotting was used to evaluate FOXO1, EMT and Wnt/β-catenin relative protein expression. RESULTS: In our study, we found that the mRNA expression level of miR-27a was significantly higher in ovarian cancer tissues and in HO8910 and OV90 cells. Functional experiments showed that miR-27a overexpression potentiated the migration and invasion of HO8910 and OV90 cells, while miR-27a inhibition reduced the cells’ migration and invasion. Moreover, miR-27a upregulated the expression of mesenchymal cell markers and downregulated the expression of epithelial cell markers, which were restored via silencing of miR-27a expression. Subsequently, miR-27a was found to directly target and suppress the expression of FOXO1. Finally, we demonstrated that miR-27a promoted the progression of ovarian cancer cells and induced the process of EMT via the Wnt/β-catenin signalling pathway through inhibition of FOXO1. CONCLUSIONS: Taken together, these results indicate that targeting miR-27a and FOXO1 could represent a strategy for anticancer therapy in ovarian cancer.
